Injection Human Interleukin 2 Global Market Report 2025

The injection human interleukin 2 market size has grown rapidly in recent years. It will grow from $1.1 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be credited to advancements in healthcare infrastructure, a higher utilization of IL-2 for autoimmune diseases, a rising number of clinical trials, an expanding pipeline of cancer immunotherapy drugs, a growing global population, and an aging demographic.

The injection human interleukin 2 market size is expected to see rapid growth in the next few years. It will grow to $1.82 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth projected for the forecast period can be linked to the rising prevalence of cancer, increased demand for immunotherapy treatments, the expansion of personalized medicine, greater funding from both government and private sectors for cancer research, and growing awareness of the benefits of immunotherapy. Key trends during this period include advancements in biotechnology and genetic engineering, the development of combination therapies, innovative drug delivery systems, improvements in drug efficacy and safety, and the development of next-generation IL-2 therapies.

The growing adoption of personalized medicine is expected to drive the expansion of the injection human interleukin 2 market. Personalized medicine customizes treatment and prevention plans based on an individual's genetic profile, lifestyle, and environment. The rising demand for personalized medicine is fueled by advances in genetic testing, which allow for more accurate diagnoses and targeted therapies that are tailored to each patient's specific needs, resulting in better outcomes and fewer side effects. This increased demand for personalized treatments enhances the use of Injection Human Interleukin 2 in customized immunotherapy regimens, where IL-2 is administered based on the patient's unique immune profile to optimize therapeutic efficacy and reduce adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 novel personalized medicines for patients with rare diseases in 2023, up from six in 2022. As a result, the growing emphasis on personalized medicine is expected to drive the market growth of injection human interleukin 2.

Innovations in low-dose interleukin-2 are gaining attention from key players in the injection human interleukin-2 market, with a focus on developing long-term treatment options. Low-dose interleukin-2 involves administering small amounts of IL-2 to specifically stimulate regulatory T cells, boosting immune tolerance while reducing inflammation and minimizing side effects. For example, in October 2024, Coya Therapeutics Inc., a U.S.-based biotech company, shared results from a double-blind study investigating the effects of subcutaneous low-dose interleukin-2 (LD IL-2) in Alzheimer's disease (AD). The study successfully met its primary and secondary endpoints, enhancing regulatory T cells (Tregs) without impacting T effector lymphocytes. Exploratory data revealed that administering low-dose IL-2 every four weeks stabilized cognition, improved cerebrospinal fluid (CSF) soluble Aβ42 levels, and stabilized CSF Neurofilament Light Chain (NfL). These results bolster confidence in Treg modulation for treating neurodegenerative diseases, particularly Alzheimer’s. COYA 301, an investigational low-dose IL-2, seeks to enhance Treg function through subcutaneous administration for modulating inflammation.

In September 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired Good Therapeutics Inc. for $250 million. This acquisition is part of Roche’s strategy to enhance its immuno-oncology pipeline by developing innovative, conditionally active Interleukin-2 treatments that selectively activate immune responses within tumors, while minimizing systemic side effects. Good Therapeutics Inc. is a US-based biotech firm, focusing on creating conditionally active interleukin-2 therapies targeting programmed cell death protein 1 for cancer immunotherapy.

Major players in the injection human interleukin 2 market are F. Hoffmann-La Roche AG, Novartis AG, Becton Dickinson and Company (BD), BioNTech SE, Corning Incorporated, Bio-Rad Laboratories Inc., StemCell Technologies Canada Inc., Clinigen Group, Iovance Biotherapeutics Inc., CUSABIO Technology LLC, Elabscience Biotechnology Inc., Enzo Biochem Inc., InvivoGen, Synthekine Inc., BPS Bioscience Inc., Xilio Therapeutics Inc., Qkine Ltd., MinneBio LLC, Akron Biotechnology LLC, Shandong Quangang Pharmaceutical Co. Ltd., and Novoprotein Scientific Inc.

North America was the largest region in the injection human interleukin 2 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in injection human interleukin 2 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Injection Human Interleukin 2 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Injection human interleukin 2 is a biologic drug primarily used in immunotherapy to stimulate the growth and activity of immune cells, such as T-cells and natural killer (NK) cells. It is a recombinant form of the naturally occurring cytokine interleukin-2, which plays a crucial role in regulating immune responses. By boosting the body's immune defenses, IL-2 injection helps to recognize and target cancer cells more effectively.

The primary product types of injection human interleukin 2 are recombinant human interleukin 2 and natural human interleukin 2. Recombinant human interleukin 2 is a synthetic version produced through recombinant DNA technology. It can be administered via subcutaneous, intravenous, or intramuscular injection and is distributed through direct sales, pharmacies, and online platforms. This drug is primarily used in oncology, immunotherapy, and for treating autoimmune diseases by various end-users, including hospitals, clinics, research institutes, and more.

The injection human interleukin 2 market research report is one of a series of new reports that provides injection human interleukin 2 market statistics, including injection human interleukin 2 industry global market size, regional shares, competitors with an injection human interleukin 2 market share, detailed injection human interleukin 2 market segments, market trends and opportunities, and any further data you may need to thrive in the injection human interleukin 2 industry. This injection human interleukin 2 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The injection human interleukin 2 market consists of sales of monoclonal antibodies, checkpoint inhibitors, cancer vaccines and immune modulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.